Divis Laboratories saw its profits grow strongly in the last quarter, with its net profit increasing by 23% compared to the same period last year. Following this, the company’s shares went up by 5%. They also announced a dividend of ₹30 for each share.
Also See: Yuan Falls on Weak China Economic Data and Increased U.S. Dollar Demand
Here’s a simple breakdown of their financial performance for the quarter ending March 2025:
- The company’s total expenses were ₹1,807 crore, which is 8.26% higher than last year.
- The cost of materials used increased by 3.67% to ₹931 crore.
- Employee costs rose by 17.84% to ₹350 crore.
- Divis Labs gained ₹10 crore from foreign exchange this quarter, compared to a loss of ₹2 crore in the same quarter last year.
- On its own, Divis Labs made a net profit of ₹667 crore, which is 25.61% more than last year, and its revenue went up by 12.26% to ₹2,536 crore.
For the full financial year ending March 2025:
- The company’s total net profit increased by 36.93% to ₹2,191 crore.
- Revenue from operations grew by 19.31% to ₹9,360 crore compared to the previous year.
In terms of expansion, Divis Labs started commercial operations of a new manufacturing unit (Unit III) at Ontimamidi Village near Kakinada, Andhra Pradesh. They invested ₹1,118 crore in assets this year, with ₹755 crore spent on this new unit.
Also See: Reliance Power and Bhutan’s Green Digital Ink Deal for ₹2,000 Cr Solar Project
The company’s board has proposed a dividend of ₹30 per share for the financial year 2024-25, which will be finalized at the upcoming Annual General Meeting.
Additionally, the board approved the retirement of L. Kishore Babu, the Chief Financial Officer (CFO), from August 1, 2025, thanking him for his service. Venkatesa Perumallu Pasumarthy will take over as the new CFO starting the same date.
Divis Laboratories is a company that makes active pharmaceutical ingredients, intermediates, and nutraceutical ingredients used in medicines and health products.
